Sarepta price target lowered to $48 from $65 at Wells Fargo

Wells Fargo lowered the firm’s price target on Sarepta (SRPT) to $48 from $65 and keeps an Overweight rating on the shares. The firm hosted 2 Duchenne Muscular Dystrophy experts to discuss recent ELEVIDYS safety and regulatory update, with focus on safety in ambulatory patients, KOL/parent/advocacy group reactions, and path forward. Wells came away hopeful that shipping to ambulatory patients could resume in 4-6 months.